Dr. Oz to testify in Medtronic/Edwards legal fight; Abbott joins Philippines typhoon relief effort;

@FierceMedDev: Analysts: Volcano could be an M&A fit for Abbott, Medtronic. More | Follow @FierceMedDev

@MarkHFierce: Inspired by a wine cork removal device, an Argentinian mechanic developed a surgical tool to aid difficult births. Story | Follow @MarkHFierce

@MichaelGFierce: From FierceDrugDelivery: DNA-delivering patch spurs bone growth. Piece | Follow @MichaelGFierce

> Physician and TV personality Dr. Mehmet Oz is set to testify as part of a lawsuit Medtronic ($MDT) filed against rival Edwards Lifesciences ($EW). Story

> Agfa-Gevaert, a Belgian company that produces, in part, equipment for X-ray machines, said revenue and operating profit hit lower-than-expected levels in the third quarter. Story

> Massachusetts device outfit GeNO wants to raise up to $50 million in a proposed IPO. The company is developing a new, patient-friendly approach to deliver inhaled nitric oxide to treat heart disease. Story

> Abbott ($ABT) will donate $450,000 in grants and healthcare products for relief efforts in the Philippines in the wake of Typhoon Haiyan. Item

> VeriTeQ, a Florida maker of implantable medical device identification and radiation dose measurement technologies, has raised $1.5 million in financing to help fuel marking and commercialization efforts. Item

> Researchers from the Korea Institute of Science and Technology and elsewhere came up with a metal made of a magnesium alloy that is biodegradable and bioabsorbable, an advance that could reshape the treatment of bone fractures. Item

Biotech News

@FierceBiotech: Merck KGaA says big M&A could jump-start stilted pipeline. Story | Follow @FierceBiotech

@JohnCFierce: Best case scenario for Lemtrada: FDA OKs for a very limited group of desperate patients. | Follow @JohnCFierce

@DamianFierce: Sanofi gets mixed FDA blessing for MS drug Lemtrada. More | Follow @DamianFierce

@EmilyMFierce: Tuberculosis R&D dropped by $30.4 million in 2012 compared with 2011. Report | Follow @EmilyMFierce

> Trio of IPO setbacks strike sour note at biotech's Wall Street party. News

> Novartis, Novavax whip up new bird flu vaccines as pandemic fears flourish. Article

> Theravance scraps ADHD program after drug flunks PhII study. More

Pharma News

@FiercePharma: Tuesday's top news: Breakthrough hep C meds aren't yet for sale, but critics already taking aim at prices. Story | Follow @FiercePharma

@EricPFierce: Actavis takes aim at North Carolina plant, 310 jobs, as it looks to cut costs. More | Follow @EricPFierce

@CarlyHFierce: CFR chief angles for meeting with Adcock Ingram after top investor nixes $1.3B deal. Story | Follow @CarlyHFierce

> Novartis, Novavax tout ability to quickly whip up pandemic flu vaccines. News

> Merck KGaA hikes forecast, eyes deals as cost cuts keep delivering. More

> Supreme Court nixes Teva's last-ditch bid to block Copaxone generics. Article

Vaccines News

> Agenus, Sanofi-NIH collaboration race to develop genital herpes vaccine. Story

> Novartis to sell first piece of vaccine unit in $1.7B deal. Article

> Polio outbreak sparks fears refugees will carry virus to Europe. Report

> Dendreon to lay off more staff as Provenge disappoints. Again. More

> Novavax presents positive Phase I data for H7N9 vaccine. Story

> U.K. adds schools to flu data-gathering project. Item

Pharma Manufacturing News

> Track-and-trace bill may be finished this week. Article

> Lilly to invest $700M in plant expansions. More

> Sandoz pulls some TB drugs in India. Report

> Dendreon hopes manufacturing can save the day. Story

> FDA red-flags dangerous counterfeit ED product. Article

> New manufacturing processes could produce bird flu vax ASAP. Item

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.